A5100454117- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Pancreatic function and diabetes
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Wound Healing and Treatments
- Diabetic Foot Ulcer Assessment and Management
- Ion Transport and Channel Regulation
- Cardiac Fibrosis and Remodeling
- Liver Disease Diagnosis and Treatment
- Pressure Ulcer Prevention and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Restless Legs Syndrome Research
- Blood Pressure and Hypertension Studies
- Chronic Kidney Disease and Diabetes
- Angiogenesis and VEGF in Cancer
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Chronic Lymphocytic Leukemia Research
- Helicobacter pylori-related gastroenterology studies
First Affiliated Hospital of GuangXi Medical University
2024-2025
Guangxi Medical University
2024-2025
Shaanxi Provincial People's Hospital
2013-2023
Shanxi Medical University
2013-2023
Merck & Co., Inc., Rahway, NJ, USA (United States)
2017-2023
First Affiliated Hospital of Fujian Medical University
2021
Fujian Medical University
2021
Handan College
2021
Xiamen University
2021
Takeda (United States)
2016
Tibial Cortex Transverse Transport (TTT) represents an innovative surgical method for treating lower extremity diabetic foot ulcers (DFUs), yet its underlying mechanisms remain elusive. Establishing animal model that closely mirrors clinical scenarios is both critical and novel elucidating the of TTT.
The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly among Chinese adults, and limited data are available on T2DM management the status glycemic control in China. We assessed efficacy oral antidiabetes drugs (OADs), glucagon-like peptide-1 (GLP-1) receptor agonists, insulin for treatment across multiple regions This was a multicenter, cross-sectional survey outpatients conducted 606 hospitals Data from all patients were collected between April June, 2011. A total 238,639...
To assess ertugliflozin in patients with type 2 diabetes who are inadequately controlled by metformin and sitagliptin.
Abstract Introduction This study assessed the safety and efficacy of ertugliflozin (an oral sodium-glucose cotransporter 2 inhibitor) vs. glimepiride in patients with type diabetes mellitus (T2DM) inadequately controlled on metformin. Methods phase III, double-blind, non-inferiority (NCT01999218) randomized HbA1c ≥ 7.0% ≤ 9.0% stable metformin 1500 mg/day 1:1:1 to 15 or 5 mg once-daily (QD), (titrated from 1 QD). The primary hypothesis was that non-inferior (non-inferiority criterion: upper...
Abstract Background Cardiac remodeling is one of the major risk factors for heart failure. In patients with type 2 diabetes, sodium–glucose cotransporter (SGLT2) inhibitors reduce first hospitalization failure, possibly through glucose-independent mechanisms in part, but underlying remain largely unknown. This study aimed to shed light on efficacy dapagliflozin reducing cardiac and potential mechanisms. Methods Sprague–Dawley (SD) rats, induced by chronic infusion Angiotensin II (Ang II) at...
VERTIS CV was a randomised, double-blind, placebo-controlled, parallel-group, multicentre cardiovascular outcomes trial that evaluated the efficacy and safety of ertugliflozin in adults with type 2 diabetes atherosclerotic disease. The primary objective to show non-inferiority placebo respect outcome, major adverse events (a composite death from causes, non-fatal myocardial infarction, or stroke). analyses reported here aimed assess cardiorenal outcomes, kidney function, other older disease...
Human Na(+)-D-glucose cotransporter (hSGLT) inhibitors constitute the newest class of diabetes drugs, blocking up to 50% renal glucose reabsorption in vivo. These drugs have potential for widespread use epidemic, but how they work at a molecular level is poorly understood. Here, we electrophysiological methods assess block SGLT1 and SGLT2 expressed human embryonic kidney 293T (HEK-293T) cells compared them classic SGLT inhibitor phlorizin. Dapagliflozin...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitalization for heart failure (HHF) and composite kidney outcomes, but mediators underlying these benefits are unknown.Among participants from VERTIS CV, a trial patients with type diabetes mellitus atherosclerotic cardiovascular disease randomized ertugliflozin versus placebo, Cox proportional hazards regression models were used evaluate percentage mediation efficacy on first HHF outcome in 26...
Abstract Aims/hypothesis This study aimed to evaluate the effect of ertugliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on eGFR and albuminuria (urine albumin/creatinine ratio [UACR]) vs glimepiride or placebo/glimepiride (non-ertugliflozin) over 104 weeks treatment in participants with type diabetes mellitus, using pooled data from two randomised controlled, active comparator studies eValuation ERTugliflozin effIcacy Safety (VERTIS) programme ( Clinicaltrials.gov NCT01999218...
Background and objectives A reduction in the rate of eGFR decline, with preservation ≥0.75 ml/min per 1.73 m 2 year, has been proposed as a surrogate for kidney disease progression. We report results from prespecified analyses assessing effects ertugliflozin versus placebo on slope eValuation ERTugliflozin effIcacy Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881). Design, setting, participants, & measurements Patients type diabetes mellitus established atherosclerotic...
Purpose: Microinjury can trigger in situ tissue repair. Bone transport consists of continuous microinjuries/microfracture and induces bone formation angiogenesis. Tibial cortex transverse (TTT) was found to promote angiogenesis at the foot healing diabetic ulcers (DFUs). However, underlying mechanism remains largely unknown. Methods: We divided 72 Sprague-Dawley rats with DFUs into control, sham, TTT groups. Wound measurement histology were performed evaluate wound processes. Enzyme-linked...
Introduction Here we report the glycemic efficacy and safety of ertugliflozin in patients VERTIS CV cardiovascular outcome trial with chronic kidney disease (CKD) stage 3. Research design methods Prespecified post-hoc analyses were performed an estimated glomerular filtration rate (eGFR) 30–<60 mL/min/1.73 m 2 at screening. The primary endpoint was week 18. Longer term changes body weight, systolic blood pressure (SBP), eGFR also evaluated. Results Among 8246 CV, 1776 had CKD 3; 1319 3A...
Background: This pooled analysis assessed the efficacy of ertugliflozin versus placebo as monotherapy or with other antihyperglycaemic agents across patient subgroups defined by demographic and disease characteristics. Methods: Data from three phase III randomised, placebo-controlled, double-blind studies (NCT01958671, NCT02033889 NCT02036515) similar designs populations were ( N = 1544). Results: At Week 26, placebo-adjusted least squares mean changes baseline in glycated haemoglobin 5 15...
Abstract Background The efficacy of ertugliflozin, a sodium–glucose cotransporter 2 inhibitor, for glycemic and blood pressure (BP) control has been demonstrated in phase 3 studies. To further evaluate the effects ertugliflozin on BP other hemodynamic parameters, an analysis was conducted pooled patient populations from these Methods This post hoc data three studies (NCT01958671, NCT02033889, NCT02036515) adults with type diabetes mellitus who received placebo, 5 mg, or 15 mg. Outcomes at 26...
Objective This study aimed to evaluate ertugliflozin in patients with overweight and obesity type 2 diabetes mellitus. Methods Data from three placebo‐controlled, randomized, Phase 3 studies were pooled. Patients baseline BMI ≥ 25 (1,377/1,544; 89%) assessed a stratification by subgroup. Results At week 26, reductions glycated hemoglobin A1c (HbA1c), fasting plasma glucose, body weight (BW), systolic blood pressure (SBP) greater versus placebo. For placebo, 5 mg, 15 respectively, least...
To assess the efficacy and safety of ertugliflozin in older patients with type 2 diabetes (T2D).This is a post hoc analysis T2D aged less than 65 years those or who participated randomized, double-blind, phase III studies ertugliflozin. Efficacy was evaluated pooled three placebo-controlled (ertugliflozin monotherapy add-on therapy). Safety seven placebo- active-controlled (including used for efficacy). Least-squares mean change from baseline calculated HbA1c, fasting plasma glucose (FPG),...
The aim of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) a single 12.5- or 25-mg dose alogliptin, dipeptidyl peptidase-4 (DPP-4) inhibitor, in pediatric (children adolescents) adult subjects with type 2 diabetes mellitus (T2DM). A randomized, open-label, multicenter was conducted subjects. Subjects two groups were randomized 1:1 receive oral alogliptin 12.5 25 mg, respectively; all gender- race-matched received mg. Blood urine samples collected at...
To assess selected cardiorenal outcomes with ertugliflozin according to use of baseline glucose-lowering agent.
Abstract Context VERTIS CV evaluated the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and atherosclerotic disease (ASCVD). Objective The aim these analyses was to assess insulin requirements over trial duration. Methods Patients received 5 mg, 15 or placebo once daily; mean follow-up 3.5 years. Time initiation who were naïve at baseline, change dose receiving baseline insulin, hypoglycemia incidence both patient groups assessed. Results In CV, duration 13.0 years;...
This prespecified exploratory analyses from VERTIS CV (NCT01986881) aimed to assess the effects of sodium-glucose cotransporter-2 (SGLT2) inhibitor ertugliflozin on glucosuria-related (glycated haemoglobin [HbA1c], uric acid, body weight) and natriuresis-related (blood pressure, haemoglobin, haematocrit, serum albumin) biomarkers according kidney function risk category.Patients with type 2 diabetes atherosclerotic cardiovascular disease were randomized placebo, 5 mg, or 15 mg (1:1:1)....
To conduct a post hoc analysis to explore indices of hepatic steatosis/fibrosis and cardiorenal outcomes in the VERTIS CV study.Patients with type 2 diabetes atherosclerotic cardiovascular (CV) disease were randomized ertugliflozin or placebo. Liver steatosis fibrosis assessed using index (HSI) fibrosis-4 (FIB-4) associations (ertugliflozin placebo data pooled, intention-to-treat set). Cardiorenal (major adverse events [MACE]; hospitalization for heart failure [HHF]/CV death; HHF; composite...
VERTIS CV is the cardiovascular outcome trial for sodium–glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin. A sub-study was conducted to assess efficacy and safety of ertugliflozin in patients with type diabetes mellitus (T2DM) inadequately glycemic-controlled on metformin a sulfonylurea (SU). Patients T2DM, established atherosclerotic disease (ASCVD), an HbA1c 7.0–10.5% stable (≥ 1500 mg/day) moderate high SU doses were randomly assigned once-daily (5 or 15 mg) placebo. The primary...